

TSCHULTZ@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER: 512/536-3020

June 4, 2001

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 Congress Avenue, Suite 2400 AUSTIN, TEXAS 78701

RECEIVED

JUN 0 8 2001

TECH CENTER 1600/2900

HOUSTON WASHINGTON, D.C. AUSTIN SAN ANTONIO DALLAS NEW YORK LOS ANGELES MINNEAPOLIS CONDON HONG KONG

FILE: ARCD:272USC1

10100267

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

Commissioner for Patents Washington, DC 20231

RE:


SN 09/754,106 "MUTATIONS IN THE DIABETES SUSCEPTIBILITY GENES HEPATOCYTE NUCLEAR FACTOR (HNF) 1 ALPHA (α), HNF-1β AND HNF-4α" - Graeme I. Bell, et al.

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Statement as Required Under 37 C.F.R. §1.825(a) and (b) and Statement as Requisted Under 37 C.F.R. §1.821(g);
- (2) Paper copy of the Sequence Listing;
- (3) Computer readable form of Sequence Listing; and
- (4) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10100267/01964.



JUN 0 8 2001

RECEIVED

TECH CENTER 1600/2900

Respectfully submitted,

Teresa J. Schultz Reg. No. 40,526

TJS/jmh Encl.: